---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-157140"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:08:27.917820+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allogene prices $175M public offering of 87.5M shares at $2.00 per share

## Summary
- Offering of 87,500,000 shares at $2.00/share; gross proceeds ~$175M before discounts and expenses.
- Underwriters granted 30-day option to buy up to 13,125,000 additional shares at same price.
- Closing expected on or about April 16, 2026, subject to customary conditions.
- Net proceeds for general corporate purposes including clinical trials and R&D.
- Goldman Sachs, Jefferies, and TD Cowen act as joint bookrunners; Piper Sandler and William Blair also joint bookrunners.

## SEC filing metadata
- accession: 0001193125-26-157140
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000119312526157140/0001193125-26-157140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000119312526157140/d283634d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-157140
- JSON: https://secwatch.observer/filing/0001193125-26-157140.json
- Plain text: https://secwatch.observer/filing/0001193125-26-157140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.